QIDP is coming from "Legislative Notice: S. 3187 – The Food and Drug Administration Safety and Innovation Act"
This section offers incentives to develop new qualified infectious disease products (QIDPs). This section provides an additional five year market exclusivity period – in addition to other exclusivity periods for which the product might qualify. It also clearly defines QIDPs as antibacterial or antifungal drugs intended to treat serious or life-threatening infections.
This section makes QIDPs eligible for priority review.
This section makes QIDPs eligible for fast track review.